Annual Industry Ranking And Forecast
Racial and ethnic diversity in clinical trials has become an imperative for many pharmaceutical companies as they seek to redress the balance, and FDA and community engagement tools are helping in the cause. While Covid-19 brought acute disruption to the clinical trials landscape last year, it has bounced back quickly, and signals of recovery can be seen in data from 2021.
Clinical Trials: Have We Finally Reached The New Normal?
Pent-up trial demand during 2020 plus trial modernization strategies yields bumper performance in 2021 as research priorities revert to pre-pandemic trends.
Racial And Ethnic Diversity In Clinical Trials: A Social And Scientific Imperative
From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.
Decentralized Trials Are Here To Stay; What Challenges Do They Face?
Decentralized trials took a leap in popularity over the past few years, in part thanks to the COVID-19 pandemic. In Vivo's sister publication Medtech Insight spoke to two executives at clinical research technology companies about running decentralized clinical trials to discuss the benefits and limitations of trials run remotely.
Under Pressure: Are Enhanced Global Efforts Enough For Trial Transparency?
Increasing scrutiny is being placed on trial sponsors and regulators to improve trial data reporting. Researchers complain that, without access to specific data, results cannot be easily duplicated, which inhibits greater understanding of how medicines might work, adversely affecting treatment decisions and health care costs. Are penalties and public reprimands enough to change behavior?
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.